Abivax SA ABVX
News
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
Abivax presents first-half 2024 financial results
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
Abivax Provides Operational and Key Program Update
Abivax increases size of Nasdaq uplisting deal